Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients with ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
Thomas Hatschek, Theodoros Foukakis, Judith Bjöhle, Tobias Lekberg, Hanna Fredholm, Ellinor Elinder, Ana Bosch, Gyula Pekar, Henrik Lindman, Aglaia Schiza, Zakaria Einbeigi, Jamila Adra, Anne Andersson, Lena Carlsson, Ann Charlotte Dreifaldt, Erika Isaksson-Friman, Susanne Agartz, Edward Azavedo, Per Grybäck, Mats HellströmHemming Johansson, Claudia Maes, Ioannis Zerdes, Johan Hartman, Yvonne Brandberg, Jonas Bergh
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients with ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial'. Together they form a unique fingerprint.